D,L-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors

Clinical Cancer Research

Volumn 2, Issue 12, 1996, Pages 1961-1968

  Vanhoefer, Udo ^a   Cao, Shousong ^a   Minderman, Hans ^a   Toth, Karoly ^a   Skenderis II, Basil S ^b   Slovak, Marilyn L ^c   Rustum, Youcef M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTHIONINE SULFOXIMINE; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; FIBROSARCOMA; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUTHIONINE SULFOXIMINE; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; FIBROSARCOMA; GENES, MDR; GLUTATHIONE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; TUMOR CELLS, CULTURED;

EID: 0030469778     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Cole, S. P. C., Bhardwaj, G., Gerlach, J. H , Mackie, J E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., and Deeley, R. G. Overexpression of a transporter gene in a multidrug-resistant human cancer cell line. Science (Washington DC), 255: 1650-1654, 1992.
2. Zaman, G. J. R., Versantvoort, C. H. M., Smit, J. J. M., Eijdems, E. W. H. M., de Haas, M., Smith, A. J., Broxterman, H. J., Mulder, N. H., de Vries, E. G. E., Baas, F., and Borst, P. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug-resistant lung cancer cell lines. Cancer Res., 53: 1747-1750, 1993.
3. Slovak, M. L., Ho, J. P., Bhardwaj, G., Kurz, E. U., Deeley, R. G., and Cole, S. P. C. Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res., 53: 3221-3225, 1993.
4. Krishnamachary, N., and Center, M. S. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane-bound glycoprotein. Cancer Res., 53: 3658-3661, 1993.
5. Schneider, E., Horton, J. K., Yang, C. H., Nakagawa, M., and Cowan, K. H. Multidrug resistance-associated gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res., 54: 152-158, 1994.
6. Grant, C. E., Valdimarsson, G., Hipfner, D. R., Almquist, K. C., Cole, S. P. C., and Deeley, R. G. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res., 54: 357-361, 1994.
7. Zaman, G. J R., Flens, M. J., van Leusden, M. R., de Haas, M., Muelder, H. S , Lankelma, J., Pinedo, H. M., Scheper, R. J., Broxterman, H. J., and Borst, P. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. USA. 91: 8822-8826, 1994.
8. Breuninger, L. M., Paul S., Gaughan, K., Miki, T., Chan, A., Aaronson, S. A., and Kruh, G. D. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res., 55: 5342-5347, 1995.
9. Cole, S. P. C , Sparks, K. E., Fraser, K., Loe, D. W., Grant, C. E., Wilson, G. M., and Deeley, R. G. Pharmacological characterization of multidrug-resistant MRP-transfected human tumor cells. Cancer Res., 54: 5902-5910, 1994.
10. Cole, S. P. C., Downes, H. F., and Slovak, M. L. Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein. Br. J. Cancer, 59: 42-46, 1989.
11. Barrand, M. A., Rhodes, T., Center, M. S., and Twentyman, P. R. Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833, and verapamil in human MDR large cell lung cancer cells expressing a 190-kDa membrane protein distinct from P-glycoprotein. Eur. J Cancer. 29A: 408-415, 1993.
12. Versantvoort, C. H. M , Schuurhuis, G J., Pinedo, H. M., Eekman, C. A., Kuiper, C. M., Lankelma, J., and Broxterman, H. J. Genistein modulates the decreased drug accumulation in non-P-glycoprotein-mediated multidrug-resistant tumour cells. Br. J. Cancer. 68: 939-941, 1993.
13. Gekeler, V., Ise, W., Sanders, K H., Ulrich, W-R., and Beck, J. The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP-associated multidrug resistance. Biochem. Biophys. Res. Comun., 208: 345-352, 1995.
14. Vanhoefer, U., Cao, S., Minderman, H., Toth, K., Scheper, R. J., Slovak, M. L., and Rustum, Y. M. PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenocrafts that overexpress the multidrug resistance protein. Clin. Cancer Res., 2: 369-377, 1996.
15. Jedlitschky, G., Leier, I., Buchholz, U., Center, M., and Keppler, D. ATP-dependent transport of glutathione 5-conjugates by the multidrug resistance-associated protein Cancer Res., 54: 4833-4836, 1994.
16. Muller, M., Meijer, C., Zaman, G. J. R., Borst, P., Scheper, R. J., Mulder, N. H , de Vries, E. G E., and Jansen, P. L. M. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl. Acad. Sci. USA, 91: 13033-13037, 1994.
17. Jedlitschky, G., Leier, I., Buchholz, U., Barnouin, K., Kurz, G., and Keppler, D. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res , 56: 988-994, 1996.
18. Versantvoort, C. H. M., Broxterman, H. J., Bagrij, T., Scheper, R. J., and Twentyman, P. R. Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br. J. Cancer, 72: 82-89, 1995.
19. Feller, N., Broxterman, H. J , Wahrer, D. C. R., and Pinedo, H. M. ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular alutathione depletion. FEBS Lett., 368: 385-388, 1995.
20. Zaman, G. J. R., Lankelma, J., van Tellingen, O., Beijnen, J., Dekker, H., Paulusma, C., Oude Elferink, R. P. J., Baas, F., and Borst, P. Role of glutathione in the export of compounds from cells by the multidrug resistance-associated protein. Proc. Natl. Acad. Sci. USA, 92: 7690-7694, 1995
21. Schneider, E., Yamazaki, H., Sinha, B. K., and Cowan, K. H. Buthionine sulphoximine-mediated sensitisation of etoposide-resistant human breast cancer MCF7 cells overexpressing the multidrug resistance-associated protein involves increased drug accumulation. Br. J. Cancer, 71: 738-743, 1995.
22. Loe, D. W., Almquist, K. D., Deeley, R. G., and Cole, S. P. C. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J. Biol. Chem., 271: 9675-9682, 1996.
23. Ford, J. M., Yang, J., and Hait, W. N. Effect of buthionine sulfoximine on toxicity of verapamil and doxorubicin to multidrug-resistant cells and mice. Cancer Res., 51: 67-72, 1991.
24. Slovak, M. L., Hoeltge, G. A., Dalton, W. S., and Trent, J. M. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res., 48: 2793-2797, 1988.
25. Shudo, N., Mizoguchi, T., Kiyosue, T., Arita, M., Yoshimura, A., Seto, K., Sakoda, R., and Akiyama, S. Two pyridine analogues with more effective ability to reverse multidrug resistance and with lower calcium channel blocking activity than their dihydropyridine counter-parts. Cancer Res., 50: 3055-3061, 1990.
26. Yin, M. B . Arredondo, M. A., Guimaraes, M. A., Schoeber, C., and Rustum, Y. M. Modulation of the in vitro cytotoxicity of doxorubicin in multidrug-resistant cells with and without P-glycoprotein expression. Cell. Pharmacol., 2: 23-28, 1995.
27. Minderman, H., Vanhoefer, U., Toth, K., Yin, M-B., Minderman, M. D., Wrzosek, C., Slovak, M. L., and Rustum, Y. M. DiOC2(3) is not substrate for multidrug resistance protein (MRP)-mediated drug efflux. Cytometry, 25: 14-20, 1996.
28. Slovak, M. L , Ho, J. P., Cole, S. P. S., Deeley, R. G., Greenberger, L., de Vries, E. G. E., Broxterman, H. J., Scheffer, G. L., and Scheper, R. J. The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or LRP gene amplification. Cancer Res., 55: 4214-4219, 1995
29. Jamali, M. A. A., Yin, M. B., Mazzoni, A., Bankusli, I., and Rustum, Y. M. Relationship between cytotoxicity, drug accumulation, and DNA damage and repair of human ovarian cancer cells treated with doxorubicin: modulation by the tiapamil analog RO11-2933. Cancer Chemother. Pharmacol., 25: 77-83, 1989
30. Toth, K., Vaughan, M. M., Slocum, H. K., Arredondo, M. A., Takita, H., Baker, R M., and Rustum, Y. M. New immunohistochemical "sandwich" staining method for mdr1 P-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, paraffin-embedded human tissues. Am. J. Pathol., 144: 227-236, 1994.
31. Flens, M. J., Izquierdo, M. A., Scheffer, G. L., Fritz, J. M., Meijer, C. J. L. M., Scheper, R. J., and Zaman, G. J. R. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res., 54: 4557-4563, 1994.
32. Griffith, O. W. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal. Biochem., 106: 207-212, 1980.
33. Doyle, L. A., Ross, D. D., Ordonez, J. V., Yang, W., Tong, Y., Belani, C. P., and Gutheil, J. C. An etoposide-resistant cancer subline overexpresses the multidrug resistance-associated protein. Br. J. Cancer, 72: 535-542, 1995.
34. Griffith, O. W., and Meister, A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (s-n-butyl-homocysteine sulfoximine). J. Biol. Chem., 254: 7558-7560, 1979.
35. Nooter, K., Westerman, A. M., Flens, M. J., Zaman, G. J. R., Scheper, R. J., van Wingerden, K. E., Burger, H., Oostrum, R., Boersma, T., Sonneveld, P., Gratama, J. W., Kok, T., Eggermont, A. M. M., Bosman, F. T., and Stoter, G. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin. Cancer Res., 1: 1301-1310, 1995.
36. Sugawara, I., Yamada, H., Nakamura, H., Sumizawa, T., Akiyama, S., Masunaga, A., and Itoyama, S. Preferential expression of the multidrug resistance-associated protein (MRP) in adenocarcinoma of the lung. Int. J. Cancer. 64: 322-325, 1995.
37. Schneider, E., Cowan, K. H., Bader, H., Toomey, S., Schwartz, G. N., Karp, J. E., Burke, P. J., and Kaufmann, S. H. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood, 85: 186-193, 1995.
38. Bailey, H. H., Mulcahy, R. T., Tutsch, K. D., Arzoomanian, R. Z., Alberti, D., Tombes, M. B., Wilding, G., Pomplun, M., and Spriggs, D. R. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J. Clin. Oncol., 12: 194-205, 1994.
39. Gallo, J. M., Brennan, J., Hamilton, T. C., Halbherr, T., Laub, P. B., Ozols, R. F., and O'Dwyer, P. J. Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO. Cancer Res., 55: 4507-4511, 1995.
40. Paul, S., Breuninger, L. M., Tew, K. D., Shen, H., and Kruh, G. D. ATP-dependent uptake of natural product cytotoxic drugs establishes MRP as a broad specifity transporter. Proc. Amer. Assoc. Cancer Res., 37: 314, 1996.
41. Tew, K. D Glutathione-associated enzymes in anticancer drug resistance. Cancer Res , 54: 4313-4320, 1994.
42. Zwelling, L. A., Slovak, M. L., Doroshow, J. H., Hinds, M., Chan, D., Parker, E., Mayes, J., Lan Sie, K., Meltzer, P. S., and Trent, J. M. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II. J. Natl. Cancer Inst., 82: 1553-1556, 1989.
43. Dulik, D. M., Fenselau, C , and Hilton, J. Characterization of melphalan-glutathione adducts whose formation is catalyzed by glutathione transferases. Biochem. Pharmacol., 35: 3409-3412, 1986.
44. Cole, S. P. C. Multidrug resistance in small cell lung cancer Can. J. Physiol. Pharmacol. 70: 313-326, 1992.